Drug intelligence / Profile preview

MSB-3163

Development stage: Unknown
Lead developer: MatriSys Bioscience
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Topical

Overview

MSB-3163 is a live biotherapeutic product being developed by MatriSys Bioscience as a topical treatment for acne vulgaris. [3, 5, 6] It consists of a specific strain of beneficial bacteria, *Staphylococcus capitis* (S. capitis E12), which was selected for its ability to selectively inhibit *Cutibacterium acnes*, a bacterium associated with acne. [3, 5] Licensed from Dr. Richard Gallo's lab at the University of California San Diego, MSB-3163 has shown greater potency against *C. acnes* than commonly used antibiotics in preclinical models. [3, 5] The company has been conducting a Phase 1b clinical study to evaluate the drug in patients. [4, 8, 10]

Beyond the preview

Go deeper on MSB-3163.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSB-3163.

Explore the full profile